Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2020 - 2025)
Historic Non-Current Deffered Revenue for Sarepta Therapeutics (SRPT) over the last 9 years, with Q1 2025 value amounting to $325.0 million.
- Sarepta Therapeutics' Non-Current Deffered Revenue changed 0.0% to $325.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $325.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $325.0 million for FY2024, which is 2562.93% down from last year.
- As of Q1 2025, Sarepta Therapeutics' Non-Current Deffered Revenue stood at $325.0 million, which was down 0.0% from $325.0 million recorded in Q4 2024.
- In the past 5 years, Sarepta Therapeutics' Non-Current Deffered Revenue ranged from a high of $641.5 million in Q1 2021 and a low of $325.0 million during Q1 2024
- Its 5-year average for Non-Current Deffered Revenue is $472.0 million, with a median of $485.0 million in 2022.
- Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first plummeted by 3298.97% in 2024, then changed by 0.0% in 2025.
- Over the past 5 years, Sarepta Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $574.2 million in 2021, then decreased by 15.54% to $485.0 million in 2022, then fell by 9.9% to $437.0 million in 2023, then decreased by 25.63% to $325.0 million in 2024, then changed by 0.0% to $325.0 million in 2025.
- Its Non-Current Deffered Revenue was $325.0 million in Q1 2025, compared to $325.0 million in Q4 2024 and $325.0 million in Q3 2024.